School of Medicine
Showing 1-10 of 11 Results
-
Zachary M. Sellers, MD, PhD
Adjunct Professor, Pediatrics - Gastroenterology
BioDr. Sellers is a pediatric physician-scientist and research and clinical development consultant. As a pediatric gastroenterologist and ion channel physiologist, Dr. Sellers' work in academia and pharma over the last 20 years has focused on improving the lives of individuals with complex and rare diseases through providing cutting-edge clinical care and advancing research and drug development. Dr. Sellers previously led a basic and translational research laboratory at Stanford, focused on epithelial ion transport and acid-base regulation using a variety of human and animal models. He is a firm believer in the exponential impact of team science and is adept working in multi-disciplinary and cross-functional teams. He seeks out strategic partnerships and opportunities that can leverage his expertise and leadership to advance innovative therapies for areas of high unmet need and to support the development of the next generation of physician-scientists. Dr. Sellers received his BS (Animal Physiology and Neuroscience) and BA (Japanese Studies) from the University of California. San Diego, his MD and PhD (Molecular and Integrative Physiology) from the University of Illinois at Urbana-Champaign, and was trained in Pediatrics and Pediatric Gastroenterology, Hepatology, and Nutrition at Stanford, where he was previously a faculty member and attending physician. He held multiple leadership positions at Stanford, including Associate Chief of Research in Gastroenterology, Director of the Stanford Children's Pancreas Program, Lead Gastroenterologist for the CF Program, Director of the CFTR Phenotyping and Theratyping Program, and Physician-Scientist Advisor for the Pediatrics Residency Program.
-
Eric Sibley, M.D., Ph.D.
Professor of Pediatrics (Gastroenterology)
Current Research and Scholarly InterestsMolecular Regulation of Intestinal Development and Maturation. We study transcriptional mechanisms regulating the spatial and temporal restriction of intestine-specific gene expression during gut development. Our approach is to characterize the function of gene-specific DNA cis elements and interacting nuclear proteins in cell culture and in transgenic animals. The goal is to relate the gene-specific control mechanisms to the broader pathways specifying acquisition of gut phenotypes.
-
Sidhartha Sinha
Assistant Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsThere are two primary and overlapping emphases of my research, both of which are driven and united by needs-based innovation and translational potential:
(1) Understanding the microenvironment of the inflamed versus normal gut in order to identify better therapeutic targets for people with immune-¬mediated GI disorders. Here, our investigations include understanding the influence and interactions of pharmacologic and dietary interventions on gut microbiome/metabolomic changes and the host immune response. In the context of providing patients with new understanding and solutions for their disease, I have led and advised on the design of both pilot and large clinical trials (including new FDA approved therapies) for anti-inflammatory therapies;
(2) Applying novel approaches and technologies (including natural language processing, computer vision, and reinforcement learning) to identify and address unmet clinical needs. In this area we have ongoing and published efforts in my lab to validate and develop solutions to pressing clinical needs. We have developed/led new drug delivery technologies with a multidisciplinary team that have shown strong potential in ongoing human IBD clinical trials. My lab has utilized both supervised and unsupervised approaches to analyze social media discourse and unstructured data sets for identifying patient needs that are rarely addressed in clinical settings. We have gained insights into patient perceptions around preventative health interventions, such as health screening and diet, including the dearth of evidence-based dietary recommendations to treat IBD (despite strong patient desire for solutions in this domain). -
Michael Snyder, Ph.D.
Stanford W. Ascherman Professor of Genetics
Current Research and Scholarly InterestsOur laboratory use different omics approaches to study a) regulatory networks, b) intra- and inter-species variation which differs primarily at the level of regulatory information c) human health and disease. For the later we have established integrated Personal Omics Profiling (iPOP), an analysis that combines longitudinal analyses of genomic, transcriptomic, proteomic, metabolomic, DNA methylation, microbiome and autoantibody profiles to monitor healthy and disease states
-
Justin L. Sonnenburg
Alex and Susie Algard Endowed Professor
Current Research and Scholarly InterestsThe goals of the Sonnenburg Lab research program are to (i) elucidate the basic mechanisms that underlie dynamics within the gut microbiota and (ii) devise and implement strategies to prevent and treat disease in humans via the gut microbiota. We investigate the principles that govern gut microbial community function and interaction with the host using a broad range of experimental approaches including studies of microbiomes in diverse human cohorts.
-
Sarah Streett
Clinical Professor, Medicine - Gastroenterology & Hepatology
BioDr. Sarah Streett is a Clinical Professor of Medicine, the Director of Inflammatory Bowel Disease Education at Stanford, and she is passionate about taking care of people with IBD. She is a national expert in treating complex IBD and initiated a multi-disciplinary approach to care with colorectal surgery, pediatrics, and nutrition. In 2018 she received the Champion of Hope Award from the Crohn’s and Colitis Foundation and serves on their National Scientific Advisory Committee. Her interests focus on fertility and pregnancy in people with IBD, developing precision approaches to IBD therapy, and the role that the microbiome and diet play in its pathogenesis. She is a primary investigator of the Stanford IBD Registry and has research projects focused on optimizing clinical outcomes in IBD, the role of the microbiota and diet in IBD and pregnancy, and applying new technologies to individualizing therapy for IBD. She is also the primary investigator on multiple industry-sponsored IBD trials.
Teaching is a top priority for Dr. Streett who feels that mentoring fellows in the development of their careers is a privilege. She has held many national leadership roles in the American Gastroenterological Association, where she has been Chair of the Practice Management and Economics Committee, and currently serves on the Government Affairs Committee. She also an appointed member of the Gastrointestinal Drug Advisory Committee at the FDA. She has represented the interests of gastroenterologists and their patients on Capitol Hill numerous times. Dr. Streett believes strongly in a collaborative approach to give patients personalized care based on the latest therapies for the treatment of IBD and is committed to mentoring the next generation of experts in the field.
